» Articles » PMID: 11356007

Signaling Domains of the Interleukin 2 Receptor

Overview
Journal Cytokine
Date 2001 May 18
PMID 11356007
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

Interleukin (IL-)2 and its receptor (IL-2R) constitute one of the most extensively studied cytokine receptor systems. IL-2 is produced primarily by activated T cells and is involved in early T cell activation as well as in maintaining homeostatic immune responses that prevent autoimmunity. This review focuses on molecular signaling pathways triggered by the IL-2/IL-2R complex, with an emphasis on how the IL-2R physically translates its interaction with IL-2 into a coherent biological outcome. The IL-2R is composed of three subunits, IL-2Ralpha, IL-2Rbeta and gammac. Although IL-2Ralpha is an important affinity modulator that is essential for proper responses in vivo, it does not contribute to signaling due a short cytoplasmic tail. In contrast, IL-2Rbeta and gammac together are necessary and sufficient for effective signal transduction, and they serve physically to connect the receptor complex to cytoplasmic signaling intermediates. Despite an absolute requirement for gammac in signaling, the majority of known pathways physically link to the receptor via IL-2Rbeta, generally through phosphorylated cytoplasmic tyrosine residues. This review highlights work performed both in cultured cells and in vivo that defines the functional contributions of specific receptor subdomains-and, by inference, the specific signaling pathways that they activate-to IL-2-dependent biological activities.

Citing Articles

The absolute number of circulating Treg cells is reduced in difficult-to-treat RA patients and is ameliorated by low-dose IL-2.

Yan H, Zi X, Yan H, Zhang X, Bai J, Gao C Front Immunol. 2025; 16:1522893.

PMID: 39981233 PMC: 11839615. DOI: 10.3389/fimmu.2025.1522893.


Revealing the role of natural killer cells in ankylosing spondylitis: identifying diagnostic biomarkers and therapeutic targets.

Chen Y, Li Y, Xu Y, Lv Q, Ye Y, Gu J Ann Med. 2025; 57(1):2457523.

PMID: 39853176 PMC: 11770870. DOI: 10.1080/07853890.2025.2457523.


"IL-2 immunotherapy for targeting regulatory T cells in autoimmunity".

Lykhopiy V, Malviya V, Humblet-Baron S, Schlenner S Genes Immun. 2023; 24(5):248-262.

PMID: 37741949 PMC: 10575774. DOI: 10.1038/s41435-023-00221-y.


Cathepsin W restrains peripheral regulatory T cells for mucosal immune quiescence.

Li J, Chen Z, Kim G, Luo J, Hori S, Wu C Sci Adv. 2023; 9(28):eadf3924.

PMID: 37436991 PMC: 10337914. DOI: 10.1126/sciadv.adf3924.


Engineering cytokine therapeutics.

Deckers J, Anbergen T, Hokke A, de Dreu A, Schrijver D, de Bruin K Nat Rev Bioeng. 2023; 1(4):286-303.

PMID: 37064653 PMC: 9933837. DOI: 10.1038/s44222-023-00030-y.